黄色软件免费观看_日本韓國三級國產歐美_在线综合亚洲欧美首页_手机看免费黄色毛片_黄色三级视频_国产 刺激 男女视觉盛宴_在线精品无码字幕无码αv_亚洲香蕉久久国产精品_温客行X周子舒车肉干_日韓歐美一區二區三區免費觀看

Entries by

EISAI AND BIOGEN ANNOUNCE PRESENTATION OF ADDITIONAL DATA FROM THE PHASE II CLINICAL TRIAL OF BAN2401 IN EARLY ALZHEIMER’S DISEASE AT THE 2018 CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced that Eisai presented the latest data from the Phase II clinical study (Study 201) of BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer’s disease, at a symposium session titled “Clinical and Biomarker Updates from BAN2401 Study 201 in Early Alzheimer’s Disease” held on October 25 at the 11th?Clinical Trials on Alzheimers Disease (CTAD) conference in Barcelona, Spain.

2018/10/25 by

Eisai China Donates Approximately RMB2.5 Million Yuan Worth of Medicines to the “Health to Countryside” Project for Five Consecutive Years

On October 23, 2018, Eisai China Inc. was invited to attend the “Health to Countryside” activity held in Duyun City, Qiannan Autonomous Prefecture, Guizhou Province by the National Committee for Education, Science, Culture, Health and Sports of Chinese People’s Political Consultative Conference (CPPCC), and donated medicines worth?RMB510,000 yuan to the local health commission.?Eisai China acts in accordance with the corporate philosophy of?human health care?(hhc) and practices social responsibilities all along, donating medicines worth RMB450,000, RMB490,000, RMB500,000, RMB540,000 and RMB510,000 respectively to this project from the year 2014 to 2018, with the total worth of medicines reaching up to approximately RMB2.5 million yuan.

2018/10/23 by

EISAI TO PRESENT LATEST DATA ON ALZHEIMER’S DISEASE / DEMENTIA PIPELINE AT 11TH CLINICAL TRIALS ON ALZHEIMER’S DISEASE CONFERENCE

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that five oral presentations including a symposium, and two poster presentations, highlighting the latest data on its Alzheimer’s disease / dementia pipeline including anti-amyloid beta (Aβ) protofibril antibody BAN2401, oral beta secretase cleaving enzyme (BACE) inhibitor elenbecestat, anti-Aβ antibody aducanumab, and dual orexin receptor antagonist lemborexant, will be given at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) conference taking place in Barcelona, Spain, from October 24 to 27. BAN2401, elenbecestat and aducanumab are being jointly developed by Eisai and Biogen Inc. (Headquarters: Cambridge, Massachusetts, United States, “Biogen”).

2018/10/18 by

Eisai and Purdue Pharma Announce Positive Topline Results of SUNRISE 2, the Second Phase 3 Pivotal Study of Lemborexant

TOKYO and STAMFORD, Conn. – October 17, 2018 – Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) and Purdue Pharma L.P. (President and CEO: Craig Landau, “Purdue Pharma”) today announced positive topline results from SUNRISE 2, a long-term Phase 3 efficacy and safety evaluation of lemborexant, an investigational agent for sleep-wake regulation currently being studied for the potential treatment of multiple sleep-wake disorders. Topline results reported today are the primary and key secondary outcomes of the study from the six-month, placebo-controlled treatment period; the study is ongoing to 12 months. Eisai and Purdue Pharma plan to present full results from SUNRISE 2 at upcoming medical meetings in 2019.

2018/10/17 by

NEW DRUG APPLICATION FOR PERAMPANEL FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES ACCEPTED IN CHINA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced that the National Medical Products Administration of China has accepted for review a New Drug Application for Eisai’s antiepileptic drug (AED) perampanel (generic name, product name: Fycompa?) as an adjunctive treatment for partial onset seizures in epilepsy patients 12 years of age and older. This NDA is the first to be submitted for perampanel in China.

2018/10/12 by

EISAI AND MERCK & CO., INC., KENILWORTH, N.J., U.S.A. ANNOUNCE CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) APPROVAL OF LENVIMA? (LENVATINIB) FOR TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARC

TOKYO and KENILWORTH, N.J. Sept. 5, 2018 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the China National Medical Products Administration (NMPA) approved the kinase inhibitor LENVIMA??(lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. In China, the application of LENVIMA was submitted in October 2017, and was designated for Priority Review by the NMPA due to LENVIMA’s significant clinical benefit compared to existing treatments, leading to approval in approximately 10 months. This approval marks the first for LENVIMA in China, where the incidence of HCC is high,1?and the first new systemic therapy approved for the first-line treatment of unresectable HCC in China in ten years.1

2018/9/5 by

LENVIMA? (LENVATINIB) CAPSULES APPROVED FOR FIRST-LINE TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) IN SOUTH KOREA

LENVIMA??(lenvatinib mesylate) as a single agent for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) from the Ministry of Food and Drug Safety (MFDS) in South Korea. An application seeking approval of LENVIMA for use in the treatment of unresectable HCC was submitted in South Korea in March 2018. This approval for LENVIMA in South Korea marks the second in Asia following approval in Japan. LENVIMA is the first new treatment option approved in ten years as a first-line systemic treatment for HCC in South Korea.

2018/8/29 by

LONG-TERM CARDIOVASCULAR OUTCOMES DATA FOR ANTI-OBESITY AGENT BELVIQ? PRESENTED AT THE EUROPEAN SOCIETY OF CARDIOLOGY AND PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced that results from the Cardiovascular Outcomes Trial (CAMELLIA-TIMI 61) in patients treated with lorcaserin hydrochloride (generic name, product name in the U.S.: BELVIQ?, “BELVIQ”) were highlighted in an oral presentation at the European Society of Cardiology (ESC) Congress 2018 held in Munich, Germany, and concurrently published in the?New England Journal of Medicine, one of the world’s most influential medical journals.1?BELVIQ is the first ever weight loss medication approved for chronic weight management which has been proven to not increase the incidence of major cardiovascular (CV) events in a dedicated long-term cardiovascular outcome trial.

2018/8/28 by

EUROPEAN COMMISSION GRANTS MARKETING AUTHORIZATION FOR LENVIMA? (LENVATINIB) AS FIRST-LINE TREATMENT IN ADULTS WITH ADVANCED OR UNRESECTABLE HEPATOCELLULAR CARCINOMA

TOKYO August 23, 2018 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has granted a marketing authorization for the oral receptor tyrosine kinase (RTK) inhibitor LENVIMA??(lenvatinib mesylate) as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy. This is the first new first-line treatment option for advanced or unresectable HCC to be approved in Europe in approximately 10 years.

2018/8/23 by

Eisai China Inc. Awarded Great Suzhou Best Employer for Second Consecutive Years

On August 22, the “2018 Great Suzhou Best Employer Award Ceremony” was held at Suzhou Jinji Lake International Convention Center. Eisai China Inc. (ECI) has been accredited Great Suzhou Best Employer for second consecutive years. The “best employer” selection project has been organized for 5 years since 2013. It is now the most influential and appealing event in Suzhou for employer brand selection. This project has successfully attracted the participation of over one thousand enterprises and the attention of millions of employees and has become an annual ceremony for the display of employer brands in Suzhou.?

2018/8/22 by